Javascript is disabled or is not supported by your browser. Please upgrade your browser or enable Javascript to navigate the interface properly.

MPM Oncology Impact Management

Latest statistics and disclosures from MPM BioImpact's latest quarterly 13F-HR filing:

Top 5 stock holdings are CGEM, OLMA, GERN, RPTX, ITOS, and represent 41.06% of MPM BioImpact's stock portfolio.
Added to shares of these 10 stocks: OLMA (+$17M), GPCR (+$12M), Cymabay Therapeutics (+$9.1M), MORF, VKTX, GERN, AVDL, FOLD, IOVA, Harpoon Therapeutics.
Started 5 new stock positions in Harpoon Therapeutics, MORF, GPCR, VKTX, Cymabay Therapeutics.
Reduced shares in these 10 stocks: Iveric Bio (-$48M), Chinook Therapeutics (-$39M), Reata Pharmaceuticals Inc Cl A (-$24M), EWTX (-$5.5M), Harpoon Therapeutics, KALV, VTYX, Oncorus, INSM, MLTX.
Sold out of its positions in Chinook Therapeutics, EWTX, Harpoon Therapeutics, Iveric Bio, Oncorus, Reata Pharmaceuticals Inc Cl A, VTYX.
MPM BioImpact was a net seller of stock by $-63M.
MPM BioImpact has $375M in assets under management (AUM), dropping by -24.57%.
Central Index Key (CIK): 0001687078

Tip: Access up to 7 years of quarterly data

Positions held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csv

Download as Excel

Portfolio Holdings for MPM BioImpact

MPM BioImpact holds 32 positions in its portfolio as reported in the September 2023 quarterly 13F filing

Company (Ticker)	Portfolio Weight	Valued At	Change in Shares	Share Count	Share Price
Cullinan Oncology Common (CGEM)	18.5	$69M		7.6M	9.05	View chart
Olema Pharmaceuticals Common (OLMA)	6.1	$23M	+301%	1.9M	12.35	View chart
Geron Corporation Common (GERN)	6.1	$23M	+16%	11M	2.12	View chart
Repare Therapeutics Common (RPTX)	5.3	$20M		1.6M	12.08	View chart
iTeos Therapeutics Common (ITOS)	5.1	$19M		1.7M	10.95	View chart
Intellia Therapeutics Common (NTLA)	4.6	$17M		545k	31.62	View chart
Moonlake Immunotherapeutics Common (MLTX)	4.5	$17M		294k	57.00	View chart
Iovance Biotherapeutics Common (IOVA)	4.0	$15M	+11%	3.3M	4.55	View chart
Crinetics Pharmaceuticals Common (CRNX)	3.8	$14M		479k	29.74	View chart
Insmed Incorporated Common (INSM)	3.6	$13M		528k	25.25	View chart
Structure Therapeutics Common (GPCR)	3.1	$12M	NEW	231k	50.42	View chart
Verve Therapeutics Common (VERV)	3.0	$11M		858k	13.26	View chart
Relay Therapeutics Common (RLAY)	3.0	$11M		1.4M	8.41	View chart
Regenxbio Common (RGNX)	2.9	$11M		657k	16.46	View chart
Cymabay Therapeutics Common	2.4	$9.1M	NEW	611k	14.91	View chart
Karuna Therapeutics Common	2.4	$9.0M		53k	169.09	View chart
Amicus Therapeutics Common (FOLD)	2.3	$8.7M	+38%	716k	12.16	View chart
Revolution Medicines Common (RVMD)	2.0	$7.6M		273k	27.68	View chart
Xeris Biopharma Holdings Common (XERS)	2.0	$7.4M		4.0M	1.86	View chart
Avadel Pharmaceuticals Common (AVDL)	1.8	$6.8M	+72%	664k	10.30	View chart
Axsome Therapeutics Common (AXSM)	1.7	$6.5M		94k	69.89	View chart
Madrigal Pharmaceuticals Common (MDGL)	1.6	$6.0M	+7%	41k	146.04	View chart
Kalvista Pharmaceuticals Common (KALV)	1.5	$5.6M	-24%	578k	9.63	View chart
Werewolf Therapeutics Common (HOWL)	1.4	$5.1M		2.4M	2.14	View chart
Travere Therapeutics Common (TVTX)	1.3	$4.9M		553k	8.94	View chart
Morphic Holding Common (MORF)	1.2	$4.6M	NEW	200k	22.91	View chart
Adaptimmune Therapeutics Sponsored ADR (ADAP)	1.1	$4.0M		5.1M	0.78	View chart
Viridian Therapeutics Common (VRDN)	1.0	$3.9M		255k	15.34	View chart
Phathom Pharmaceuticals Common (PHAT)	1.0	$3.6M	+23%	347k	10.37	View chart
Viking Therapeutics Common (VKTX)	1.0	$3.6M	NEW	325k	11.07	View chart
Inozyme Pharma Common (INZY)	0.4	$1.4M		327k	4.20	View chart
Harpoon Therapeutics Common	0.3	$1.3M	NEW	320k	4.03	View chart

Past Filings by MPM BioImpact

SEC 13F filings are viewable for MPM BioImpact going back to 2019

MPM BioImpact 2023 Q3 filed Nov. 14, 2023
BioImpact Capital 2023 Q2 filed Aug. 14, 2023
BioImpact Capital 2023 Q1 filed May 12, 2023
BioImpact Capital 2022 Q4 filed Feb. 14, 2023
BioImpact Capital 2022 Q3 filed Nov. 14, 2022
BioImpact Capital 2022 Q2 filed Aug. 11, 2022
BioImpact Capital 2022 Q1 filed May 13, 2022
BioImpact Capital 2021 Q4 filed Feb. 11, 2022
BioImpact Capital 2021 Q3 filed Nov. 15, 2021
MPM Oncology Impact Management 2021 Q2 filed Aug. 13, 2021
MPM Oncology Impact Management 2021 Q1 filed May 13, 2021
MPM Oncology Impact Management 2020 Q4 restated filed Feb. 24, 2021
MPM Oncology Impact Management 2020 Q4 filed Feb. 16, 2021
MPM Oncology Impact Management 2020 Q3 restated filed Nov. 19, 2020
MPM Oncology Impact Management 2020 Q3 filed Nov. 13, 2020
MPM Oncology Impact Management 2020 Q2 filed Aug. 12, 2020

View all past filings

Disclaimers: stockzoa.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on stockzoa.com represent a recommendation to purchase or sell a stock. The information on this site is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall stockzoa.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content available on stockzoa.com, or relating to the use of, or inability to use, stockzoa.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

Fund Directory: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X-Z